Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) is 8.42% higher on its value in year-to-date trading and has touched a low of $143.96 and a high of $304.39 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALNY stock was last observed hovering at around $263.24 in the last trading session, with the day’s loss setting it -8.11%.
Currently trading at $255.13, the stock is 5.54% and 2.50% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.52 million and changing -3.08% at the moment leaves the stock -1.37% off its SMA200. ALNY registered 73.13% gain for a year compared to 6-month loss of -11.08%. The firm has a 50-day simple moving average (SMA 50) of $248.8954 and a 200-day simple moving average (SMA200) of $258.6772.
The stock witnessed a -0.25% gain in the last 1 month and extending the period to 3 months gives it a -7.95%, and is 5.16% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.25% over the week and 6.08% over the month.
Alnylam Pharmaceuticals Inc (ALNY) has around 2230 employees, a market worth around $33.19B and $2.25B in sales. Fwd P/E is 143.46. Profit margin for the company is -12.37%. Distance from 52-week low is 77.22% and -16.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-10.47%).
with sales reaching $624.63M over the same period.The EPS is expected to grow by 41.23% this year, but quarterly earnings will post 29.23% year-over-year. Quarterly sales are estimated to shrink -5.33% in year-over-year returns.
917.0 institutions hold shares in Alnylam Pharmaceuticals Inc (ALNY), with institutional investors hold 100.94% of the company’s shares. The shares outstanding are 129.29M, and float is at 124.35M with Short Float at 2.46%. Institutions hold 97.03% of the Float.
The top institutional shareholder in the company is CAPITAL WORLD INVESTORS with over 14.97 million shares valued at $3.64 billion. The investor’s holdings represent 11.8133 of the ALNY Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.51 million shares valued at $3.04 billion to account for 9.8694 of the shares outstanding. The other top investors are FMR LLC which holds 12.16 million shares representing 9.5982 and valued at over $2.96 billion, while BLACKROCK INC. holds 7.5337 of the shares totaling 9.55 million with a market value of $2.32 billion.
Alnylam Pharmaceuticals Inc (ALNY) Insider Activity
The most recent transaction is an insider sale by Garg Pushkal, the company’s CMO & EVP Dev & Med Affairs. SEC filings show that Garg Pushkal sold 5,445 shares of the company’s common stock on Mar 24 ’25 at a price of $300.00 per share for a total of $1.63 million. Following the sale, the insider now owns 20221.0 shares.
Alnylam Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 21 ’25 that Garg Pushkal (CMO & EVP Dev & Med Affairs) sold a total of 4,321 shares of the company’s common stock. The trade occurred on Mar 21 ’25 and was made at $285.00 per share for $1.23 million. Following the transaction, the insider now directly holds 20221.0 shares of the ALNY stock.
Still, SEC filings show that on Mar 24 ’25, PYOTT DAVID E I (Director) disposed off 7,440 shares at an average price of $299.00 for $2.22 million. The insider now directly holds 136 shares of Alnylam Pharmaceuticals Inc (ALNY).
